Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator.

Schou, Magnus; Ewing, Pär; Cselenyi, Zsolt; Fridén, Markus; Takano, Akihiro; Halldin, Christer; Farde, Lars

Schou, Magnus; Ewing, Pär; Cselenyi, Zsolt; Fridén, Markus; Takano, Akihiro; Halldin, Christer; Farde, Lars.

Afiliación

Schou M; PET Science Centre, Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Karolinska Institutet, Stockholm, Sweden. magnus.schou@astrazeneca.com.
Ewing P; Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76, Stockholm, Sweden. magnus.schou@astrazeneca.com.
Cselenyi Z; Respiratory, Inflammation and Autoimmunity IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Fridén M; PET Science Centre, Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.
Takano A; Respiratory, Inflammation and Autoimmunity IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Halldin C; Translational PKPD, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Farde L; Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, SE-171 76, Stockholm, Sweden.

EJNMMI Res ; 9(1): 9, 2019 Jan 29.

Article en En | MEDLINE | ID: mdl-30694407

Palabras clave

Ipratropium; Lungs; Muscarinic receptors; PET

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: EJNMMI Res Año: 2019 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Alemania

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google